Autres langues Gilead Sciences, Inc. Sao Paulo

Actions

GILD34

BRGILDBDR000

Produits pharmaceutiques

Marché Fermé - Sao Paulo 21:52:36 11/09/2026			Varia. 5j.	Varia. 1 janv.
61,27 ^BRL	+0,44%		-4,65%	+6,87%

10/09	Transcript : Gilead Sciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
10/09	Gilead Sciences, Inc. : HSBC reste à l'achat	ZM

Autres langues

08/09	Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead
08/09	Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
08/09	Assembly Biosciences, Inc. and Gilead Sciences, Inc. Exercise U.S. Profit-Share Option for HSV Helicase-Primase Inhibitor Program
08/09	Gilead Sciences Opens Research Center At Foster City Headquarters
08/09	Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
07/09	Gilead Sciences Announces FDA Approval for Bixlenvo as A Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv
03/09	AbbVie's blood cancer therapy lowers disease progression, death risk in trial
01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
28/08	Afternoon Meeting: Warsh entra en escena
28/08	Warsh Takes the Stage
28/08	Morning Meeting: Zwei Märkte, zwei Geschichten
28/08	A tale of two markets
28/08	Gilead Sciences : Breaks Ground on New Biologics Facility as Part of $32 Billion U.S. R&D and Manufacturing Investment
28/08	Gilead Sciences Wins FDA Approval for HIV Pill Bixlenvo
27/08	US FDA approves Gilead's once-daily combination pill for HIV treatment
27/08	U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
27/08	Gilead Sciences Announces FDA Approval Of Bixlenvo For Virologically Suppressed Adults With HIV
27/08	FDA Approves Gilead Sciences' Bixlenvo for Certain Adults With HIV
26/08	Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
25/08	Afternoon Meeting: Wall Street exige resultados
25/08	Wall Street Wants Receipts
25/08	Positief nieuws voor Lakefront uit de VS
25/08	Morning Meeting: ¿Mucho ruido y pocas nueces?
25/08	Morning Meeting: Viel Lärm um nichts?
25/08	Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US